Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2041 to 2050 of 2578 total matches.
Comparison Table: Drugs for Alzheimer's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
of galantamine
▶ Approval based on earlier studies with galantamine
Rivastigmine – generic
1.5, 3, 4.5, 6 mg ...
View the Comparison Table: Drugs for Alzheimer's Disease
In Brief: HPV Vaccine for Boys?
The Medical Letter on Drugs and Therapeutics • Mar 07, 2011 (Issue 1359)
%
of anal cancer.1 Gardasil is highly effective in preventing
infection with HPV types 6, 11, 16 and 18 ...
The FDA has approved a new indication for prevention of anal cancer and anal intraepithelial neoplasia in both sexes for the human papillomavirus (HPV) vaccine Gardasil (Merck). This vaccine is already FDA-approved for prevention of cervical cancer and genital warts in females 9-26 years old and for prevention of genital warts in males 9-26 years old. HPV types 6 and 11 cause about 90% of genital warts. Types 16 and 18 cause more than 70% of cervical cancer and about 80% of anal cancer.1 Gardasil is highly effective in preventing infection with HPV types 6, 11, 16 and 18 in both males and...
In Brief: Budeprion XL 300 Has Been Withdrawn
The Medical Letter on Drugs and Therapeutics • Oct 29, 2012 (Issue 1402)
XL matrix released more
bupropion in the first 4 hours than the Wellbutrin XL
membrane did.1 ...
The FDA has asked Impax Laboratories/Teva Pharmaceuticals to stop production and distribution of Budeprion XL 300 mg, a generic extended-release formulation of the antidepressant bupropion (Wellbutrin XL), because it has found that Budeprion XL 300 mg releases bupropion more rapidly than Wellbutrin XL 300 mg, the original brand name product. Patients switched from the brand name to the generic formulation have complained for years that the generic was less effective and caused more side effects than the original formulation. In 2007, ConsumerLab.com, an independent laboratory, conducted...
In Brief: Oxytrol OTC
The Medical Letter on Drugs and Therapeutics • Sep 16, 2013 (Issue 1425)
, frequency,
and incontinence with no obvious cause, occurs mainly
in older women.1 Behavioral modification ...
The transdermal patch formulation of the anticholinergic drug oxybutynin (Oxytrol – Watson) is now available over the counter (OTC) as Oxytrol for Women (MSD) for use in women with overactive bladder (OAB). It is the first treatment for OAB to become available OTC. Oxybutynin remains available only by prescription for men.OAB, characterized by symptoms of urgency, frequency, and incontinence with no obvious cause, occurs mainly in older women.1 Behavioral modification, including fluid schedules, timed voiding, pelvic exercises, and urge suppression, is usually tried first.Anticholinergic...
In Brief: Dinutuximab (Unituxin) for High-Risk Neuroblastoma (online only)
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
on the surface of neuroblastoma
cells.1
Dinutuximab received a priority review and orphan
drug designation ...
The FDA has approved use of dinutuximab (Unituxin [yoo ni tux' in] – United Therapeutics) in combination with interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), and isotretinoin for treatment of children with high-risk neuroblastoma who previously responded to first-line therapies. Dinutuximab is a monoclonal antibody that binds to GD2, a glycolipid that is overexpressed on the surface of neuroblastoma cells.1Dinutuximab received a priority review and orphan drug designation. Approval was based on the results of an open-label trial in 226 patients with high-risk...
In Brief: Cholic Acid (Cholbam) for Bile Acid Synthesis Disorders
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
trials survived for more
than 3 years.1 Some of these survivors have been treated
successfully for more ...
The FDA has approved oral cholic acid (Cholbam – Retrophin) for treatment of children and adults with bile acid synthesis disorders caused by single enzyme defects and for adjunctive treatment of peroxisomal disorders such as Zellweger spectrum disorders in patients who have liver disease, steatorrhea, or complications from fat-soluble vitamin malabsorption. Patients with these rare inborn errors of bile acid metabolism cannot synthesize primary bile acids such as cholic acid, resulting in reduced bile flow, decreased absorption of fat and fat-soluble vitamins, and development of liver...
Safety of Aggressive Statin Therapy
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004 (Issue 1196)
for those at moderately high
risk.
1,2
A likely consequence of these recommendations is increased use ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
arthritis.1 Updated guidelines for treatment
of psoriatic arthritis have recently been published.2 ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
In Brief: Benzonatate Warning
The Medical Letter on Drugs and Therapeutics • Feb 07, 2011 (Issue 1357)
benzonatate (Tessalon Perles, and others) by
children less than 10 years old can be fatal.1 This widely ...
The FDA recently warned that accidental ingestion of the antitussive benzonatate (Tessalon Perles, and others) by children less than 10 years old can be fatal.1 This widely prescribed oral agent, which has been available in the US since 1958, can also cause severe morbidity and death in older children and adults, and not only in overdosage.Benzonatate is a polyglycol derivative structurally related to procaine and tetracaine. It acts peripherally on stretch receptors in the lower respiratory tract to suppress the cough reflex. If the patient chews or sucks the liquid-filled capsules or...
In Brief: Severe Bradycardia with Sofosbuvir and Amiodarone
The Medical Letter on Drugs and Therapeutics • Apr 13, 2015 (Issue 1466)
, and others).1 Symptomatic bradycardia
was reported following initiation of treatment with
Harvoni ...
The FDA recently announced changes in the labeling of the hepatitis C drugs Sovaldi (sofosbuvir) and Harvoni (sofosbuvir/ledipasvir) to warn about a risk of serious and potentially fatal bradycardia when either drug is taken with the antiarrhythmic drug amiodarone (Cordarone, and others).1 Symptomatic bradycardia was reported following initiation of treatment with Harvoni or with Sovaldi plus simeprevir (Olysio) or the investigational antiviral drug daclatasvir in 9 patients already taking amiodarone; it occurred within 24 hours of starting hepatitis C therapy in 6 patients and within 2-12...